-
Featured Authors
Business of Biotech
Archive
- April 2013 (1)
- February 2013 (2)
- January 2013 (1)
- October 2012 (1)
- September 2012 (3)
- August 2012 (1)
- January 2012 (3)
- December 2011 (2)
- October 2011 (3)
- August 2011 (3)
- July 2011 (2)
- June 2011 (12)
- April 2011 (2)
- January 2010 (1)
- November 2009 (1)
- October 2009 (47)
- September 2009 (37)
- August 2009 (1)
- June 2008 (3)
- May 2008 (2)
- April 2008 (1)
- February 2008 (6)
Category Archives: Business of Biotech
A Start-Up Model Worthy of Consideration
Biotech LLCs are getting a lot of attention lately, and perhaps rightfully so. The Wall Street Journal’s Brian Gormley recently talked to Albert L. Sokol, a partner with Edwards Wildman Palmer, about the two venture-backed biotechs – Forma Therapeutics and Viamet Pharmaceuticals – that he helped convert to LLCs. In the WSJ article – Biotech Start-Ups See Benefits from Changing Structure, Lawyer Says – Sokol describes the benefits to start-ups and their venture investors, as Read More >
Colorado Biotech’s Big Day
Last week, the Colorado BioScience Association (CBSA) hosted its annual BioWest Conference – a one day event attended by more than 500 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. Colorado Public Radio’s Ryan Warner interviewed CBSA’s April Giles about the conference and several innovative biotech companies in the state. Give it a listen.
New Report Shows Strength of Massachusetts’ Biotech Industry
If you read this blog, there’s a good chance you already know that Massachusetts is one of the biggest biotech hubs in the world. The Commonwealth’s successes in biotech economic development can be attributed to a number of things. Perhaps foremost, its world-class universities, such as MIT and Harvard, continue to churn out the innovation that keeps venture groups interested. Meanwhile, established biotechs and Big Pharma continue to focus more and more R&D work in Read More >
Award Honors Rhode Island Biotech Excellence
Know somebody in Rhode Island biotech that deserves special recognition? Then nominate them for Tech Collective’s Rhode Island Bioscience Awards. Check it out, nominate, and apply here. Nominations are due September 24th, Applications are due October 1st.
Managing in a Cost-Constrained Environment
By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >
